QooLabs SBIR Phase 2: Develop a point-of-care (POC) diagnostic kit designed for the serological detection of HSV-1 and HSV-2 with high sensitivity and specificity. (75N93024C00046)
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health forecasts a new requirement, titled "QooLabs SBIR Phase 2" (75N93024C00046), to develop a point-of-care diagnostic kit for serological detection of HSV-1 and HSV-2 with high sensitivity and specificity, under a Total Small Business set-aside. The estimated solicitation release date is August 1, 2026, and the estimated award date is September 1, 2026, both of which precede this forecast's November 14, 2026 posting date. The effort continues product development of completed early-stage research to produce a rapid, inexpensive test that distinguishes type 1 and type 2 infections, addressing insufficient sensitivity and specificity in existing tests and the cost and turnaround time of the western blot standard.
The estimated award value range is $1.5 million to $3.0 million, under NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences, except Nanotechnology and Biotechnology). Points of contact are Callie Prassinos, Contracting Officer at NIH (callie.prassinos@nih.gov, +1 240-669-5155), and Jonathan Glock at the National Institutes of Health (jglock@niaid.nih.gov).
Forecast text
An application to continue the product development of this successfully completed early-stage research for a diagnostic to detect Herpes Simplex Virus and differentiate between type 1 and type 2 infections in people. Existing tests have insufficient sensitivity and specificity, while the western blot assay, the current standard, is too costly and time consuming for widespread use. A rapid, inexpensive test that can detect and distinguish type1 and type 2 infections with high sensitivity and specificity is needed to improve medical care and public health surveillance of these infections.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast